Navigation Links
Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
Date:10/30/2008

JENA, Germany, October 30 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of cardiac occlusion devices, today announced that it has won its litigation case in The Hague, Holland, against AGA Medical Inc. regarding non-infringement of the Dutch version of the European patent; EP 0808138.

The patent court in The Hague stated that the disputed Occlutech products do not infringe the Dutch part of; EP 0808138 (equivalent of German patent DE 695 34 505.2) held by AGA Medical. In reaching its decision, the Dutch court had full access to the now appealed 2007 German District Court's ruling resulting from litigation initiated by AGA Medical in 2006.

Patent infringement litigation against a previous version of the occluder was originally filed in Germany by AGA Medical Inc. In Occlutech's view, AGA Medical argued for an extraordinarily broad interpretation of its granted patent claims, contributing to Occlutech's defeat in the first instance district court's ruling. The broad scope of the claim, interpreted before the German court in 2007, was however not accepted by the European Patent Office's examiners during the original patent granting procedure. This and several other factors created significant and in Occlutech's view justified reasons for appealing the district court ruling in Germany and for Occlutech to initiate non-infringement proceedings internationally and, in particular, before the patent court in The Hague, Holland. The Dutch patent court's ruling will become final if no appeal is filed.

In a statement, Tor Peters, Chairman of Occlutech AB, says: "We are very pleased with the decision of the patent court in The Hague, which had access to all relevant information available, including information submitted at the appeal proceedings in Germany. This shows that Occlutech's patented technology is substantially different from AGA's and we look forward to continue our surge, establishing a global presence."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

Contacts:

Tor Peters

tor.peters@occlutech.se

+46-42-33-65-20

Susanne Goransson

susanne.goransson@occlutech.net

+46-42-33-65-21


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Botaneco obtains $2.4 million in funding from AVAC
5. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
6. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
7. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
8. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
9. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
10. Biofisica Obtains $2.3 Million in Financing From Investors
11. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):